Idioma:

Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study

Mateos, Maria‐Victoria ; Orlowski, Robert Z. ; Ocio, Enrique M. ; Rodríguez‐Otero, Paula ; Reece, Donna ; Moreau, Philippe ; Munshi, Nikhil ; Avigan, David E. ; Siegel, David S. ; Ghori, Razi ; Farooqui, Mohammed Z. H. ; Marinello, Patricia ; San-Miguel, Jesus

British journal of haematology, 2019-09, Vol.186 (5), p.e117-e121 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Título:
Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study
Autor: Mateos, Maria‐Victoria ; Orlowski, Robert Z. ; Ocio, Enrique M. ; Rodríguez‐Otero, Paula ; Reece, Donna ; Moreau, Philippe ; Munshi, Nikhil ; Avigan, David E. ; Siegel, David S. ; Ghori, Razi ; Farooqui, Mohammed Z. H. ; Marinello, Patricia ; San-Miguel, Jesus
Assuntos: Dexamethasone ; Hematology ; Immunotherapy ; lenalidomide ; Monoclonal antibodies ; Multiple myeloma ; Pembrolizumab ; relapsed/refractory ; Targeted cancer therapy
É parte de: British journal of haematology, 2019-09, Vol.186 (5), p.e117-e121
Notas: SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ObjectType-Feature-3
Editor: England: Blackwell Publishing Ltd
Idioma: Inglês

Links

Voltar para lista de resultados